{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010560","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.318663+00:00","generated_at":"2026-06-17T07:18:25.525834+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ZyVersa reports $14.1M net loss for 2022, cash $5.9M; plans VAR 200 trial in Q4 2023","bullets":["No revenue in 2022; net loss of $14.1M combined (up 75% from $8.1M in 2021).","Cash $5.9M as of Dec 31, 2022; expects to need additional financing to continue operations.","Completed business combination with Larkspur Health in Dec 2022; began trading on Nasdaq under ZVSA.","Plans investigator-initiated trial for VAR 200 in FSGS and up to two other renal indications in Q4 2023.","IC 100 preclinical program to complete in 2023; IND submission expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010560","json":"https://secwatch.observer/filing/0001493152-23-010560.json","markdown":"https://secwatch.observer/filing/0001493152-23-010560.md","text":"https://secwatch.observer/filing/0001493152-23-010560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223010560/0001493152-23-010560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223010560/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:18:25.525834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cbbae0645f42ab6e3c5981e67f2ac79dccf24c76","claim":"ZyVersa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA , or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drug candidates for the treatment of renal and inflammatory diseases with high unmet medical needs, today provides a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223010560/0001493152-23-010560-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}